Elucent Medical, a guided surgical technology company, will receive $30 million in growth capital from Trinity Capital.

WHAT IT DOES

Elucent Medical's flagship product EnVisio System utilizes a spatial field generator measuring continuous data points across multiple planes to display exact 3D positioning of the SmartClip marker and SmartSensor that is used to guide soft-tissue surgical excision.

Elucent will use the funds to scale operations and expand its innovation and commercialization initiatives. 

"Our EnVisio System gives surgeons confidence before, during and after their surgical procedures so they know they have delivered unparalleled accuracy and precision for their patients," Jason Pesterfield, CEO of Elucent, said in a statement.

"We are in scale mode and are excited to partner with Trinity Capital. Trinity Capital's investment will be key to our continued acceleration of our innovation and commercialization efforts."

MARKET SNAPSHOT

Elucent president and CEO Jason Pesterfield, told MobiHealthNews that the company raised $44 million in a Series C funding round in early 2024.

Other companies in this space include MediViewXR, a medtech company that utilizes augmented reality and develops extended reality surgical navigation used in ablation and biopsy of cancerous tumors. 

In 2024, GE HealthCare and MediViewXR announced the successful clinical use of their codeveloped OmnifyXR Interventional Suite System. OmnifyXR pairs GE's imaging technology with MediView's AR and surgical navigation platform to help physicians better assess a patient's anatomy, make more informed clinical decisions and allow for remote collaboration by care teams in different locations.

AI-enabled surgical technology company Proprio secured $43 million in Series B funding in 2023 from new and existing investors, including Bird B. 

The company offers a surgical navigation platform, dubbed Paradigm, which utilizes light field technology and artificial intelligence to generate 3D visualization of surgery, allowing for intraoperative scans to be seen in real-time. It also offers a platform called Volumetric Intelligence that combines medical images with data from Paradigm's sensor.    

Boston-based Activ Surgical is a digital surgery company that focuses on improving surgical efficiency, accuracy, patient outcomes and accessibility for both endoscopic and robotically-assisted procedures. 

Activ Surgical’s surgical software platform is driven by computer vision, artificial intelligence, analytics and machine learning to enhance a surgeon’s intraoperative decision-making and reduce unintended and preventable surgical complications.

In 2021, Activ Surgical announced a $45 million Series B funding round.